Copyright Reports & Markets. All rights reserved.

Covid-19 Impact on Global Adipose Derived Stem Cell Therapy Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Adipose Derived Stem Cell Therapy Revenue
  • 1.4 Covid-19 Implications on Market by Type
    • 1.4.1 Global Adipose Derived Stem Cell Therapy Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Autologous Stem Cells
    • 1.4.3 Allogeneic Stem Cells
  • 1.5 Market by Application
    • 1.5.1 Global Adipose Derived Stem Cell Therapy Market Share by Application: 2020 VS 2026
    • 1.5.2 Therapeutic Application
    • 1.5.3 Research Application
  • 1.6 Coronavirus Disease 2019 (Covid-19): Adipose Derived Stem Cell Therapy Industry Impact
    • 1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.6.2 Covid-19 Impact: Commodity Prices Indices
    • 1.6.3 Covid-19 Impact: Global Major Government Policy
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends

  • 2.1 Covid-19 Implications on Global Adipose Derived Stem Cell Therapy Market Perspective (2015-2026)
  • 2.2 Covid-19 Implications on Global Adipose Derived Stem Cell Therapy Growth Trends by Regions
    • 2.2.1 Adipose Derived Stem Cell Therapy Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Adipose Derived Stem Cell Therapy Historic Market Share by Regions (2015-2020)
    • 2.2.3 Adipose Derived Stem Cell Therapy Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Adipose Derived Stem Cell Therapy Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Adipose Derived Stem Cell Therapy Players (Opinion Leaders)

3 Covid-19 Implications on Competition Landscape by Key Players

  • 3.1 Global Top Adipose Derived Stem Cell Therapy Players by Market Size
    • 3.1.1 Global Top Adipose Derived Stem Cell Therapy Players by Revenue (2015-2020)
    • 3.1.2 Global Adipose Derived Stem Cell Therapy Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Adipose Derived Stem Cell Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Adipose Derived Stem Cell Therapy Market Concentration Ratio
    • 3.2.1 Global Adipose Derived Stem Cell Therapy Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Adipose Derived Stem Cell Therapy Revenue in 2019
  • 3.3 Adipose Derived Stem Cell Therapy Key Players Head office and Area Served
  • 3.4 Key Players Adipose Derived Stem Cell Therapy Product Solution and Service
  • 3.5 Date of Enter into Adipose Derived Stem Cell Therapy Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Covid-19 Implications on Market Size by Type (2015-2026)

  • 4.1 Global Adipose Derived Stem Cell Therapy Historic Market Size by Type (2015-2020)
  • 4.2 Global Adipose Derived Stem Cell Therapy Forecasted Market Size by Type (2021-2026)

5 Covid-19 Implications on Market Size by Application (2015-2026)

  • 5.1 Global Adipose Derived Stem Cell Therapy Market Size by Application (2015-2020)
  • 5.2 Global Adipose Derived Stem Cell Therapy Forecasted Market Size by Application (2021-2026)

6 North America Impact of COVID-19

  • 6.1 North America Adipose Derived Stem Cell Therapy Market Size (2015-2020)
  • 6.2 Adipose Derived Stem Cell Therapy Key Players in North America (2019-2020)
  • 6.3 North America Adipose Derived Stem Cell Therapy Market Size by Type (2015-2020)
  • 6.4 North America Adipose Derived Stem Cell Therapy Market Size by Application (2015-2020)

7 Europe Impact of COVID-19

  • 7.1 Europe Adipose Derived Stem Cell Therapy Market Size (2015-2020)
  • 7.2 Adipose Derived Stem Cell Therapy Key Players in Europe (2019-2020)
  • 7.3 Europe Adipose Derived Stem Cell Therapy Market Size by Type (2015-2020)
  • 7.4 Europe Adipose Derived Stem Cell Therapy Market Size by Application (2015-2020)

8 China Impact of COVID-19

  • 8.1 China Adipose Derived Stem Cell Therapy Market Size (2015-2020)
  • 8.2 Adipose Derived Stem Cell Therapy Key Players in China (2019-2020)
  • 8.3 China Adipose Derived Stem Cell Therapy Market Size by Type (2015-2020)
  • 8.4 China Adipose Derived Stem Cell Therapy Market Size by Application (2015-2020)

9 Japan Impact of COVID-19

  • 9.1 Japan Adipose Derived Stem Cell Therapy Market Size (2015-2020)
  • 9.2 Adipose Derived Stem Cell Therapy Key Players in Japan (2019-2020)
  • 9.3 Japan Adipose Derived Stem Cell Therapy Market Size by Type (2015-2020)
  • 9.4 Japan Adipose Derived Stem Cell Therapy Market Size by Application (2015-2020)

10 Southeast Asia Impact of COVID-19

  • 10.1 Southeast Asia Adipose Derived Stem Cell Therapy Market Size (2015-2020)
  • 10.2 Adipose Derived Stem Cell Therapy Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Adipose Derived Stem Cell Therapy Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Adipose Derived Stem Cell Therapy Market Size by Application (2015-2020)

11 India Impact of COVID-19

  • 11.1 India Adipose Derived Stem Cell Therapy Market Size (2015-2020)
  • 11.2 Adipose Derived Stem Cell Therapy Key Players in India (2019-2020)
  • 11.3 India Adipose Derived Stem Cell Therapy Market Size by Type (2015-2020)
  • 11.4 India Adipose Derived Stem Cell Therapy Market Size by Application (2015-2020)

12 Central & South America Impact of COVID-19

  • 12.1 Central & South America Adipose Derived Stem Cell Therapy Market Size (2015-2020)
  • 12.2 Adipose Derived Stem Cell Therapy Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Adipose Derived Stem Cell Therapy Market Size by Type (2015-2020)
  • 12.4 Central & South America Adipose Derived Stem Cell Therapy Market Size by Application (2015-2020)

13Key Players Profiles

  • 13.1 AlloCure
    • 13.1.1 AlloCure Company Details
    • 13.1.2 AlloCure Business Overview and Its Total Revenue
    • 13.1.3 AlloCure Adipose Derived Stem Cell Therapy Introduction
    • 13.1.4 AlloCure Revenue in Adipose Derived Stem Cell Therapy Business (2015-2020))
    • 13.1.5 AlloCure Recent Development and Reaction to COVID-19
  • 13.2 Antria
    • 13.2.1 Antria Company Details
    • 13.2.2 Antria Business Overview and Its Total Revenue
    • 13.2.3 Antria Adipose Derived Stem Cell Therapy Introduction
    • 13.2.4 Antria Revenue in Adipose Derived Stem Cell Therapy Business (2015-2020)
    • 13.2.5 Antria Recent Development and Reaction to COVID-19
  • 13.3 Celgene Corporation
    • 13.3.1 Celgene Corporation Company Details
    • 13.3.2 Celgene Corporation Business Overview and Its Total Revenue
    • 13.3.3 Celgene Corporation Adipose Derived Stem Cell Therapy Introduction
    • 13.3.4 Celgene Corporation Revenue in Adipose Derived Stem Cell Therapy Business (2015-2020)
    • 13.3.5 Celgene Corporation Recent Development and Reaction to COVID-19
  • 13.4 Cellleris
    • 13.4.1 Cellleris Company Details
    • 13.4.2 Cellleris Business Overview and Its Total Revenue
    • 13.4.3 Cellleris Adipose Derived Stem Cell Therapy Introduction
    • 13.4.4 Cellleris Revenue in Adipose Derived Stem Cell Therapy Business (2015-2020)
    • 13.4.5 Cellleris Recent Development and Reaction to COVID-19
  • 13.5 Corestem
    • 13.5.1 Corestem Company Details
    • 13.5.2 Corestem Business Overview and Its Total Revenue
    • 13.5.3 Corestem Adipose Derived Stem Cell Therapy Introduction
    • 13.5.4 Corestem Revenue in Adipose Derived Stem Cell Therapy Business (2015-2020)
    • 13.5.5 Corestem Recent Development and Reaction to COVID-19
  • 13.6 Cytori Therapeutics
    • 13.6.1 Cytori Therapeutics Company Details
    • 13.6.2 Cytori Therapeutics Business Overview and Its Total Revenue
    • 13.6.3 Cytori Therapeutics Adipose Derived Stem Cell Therapy Introduction
    • 13.6.4 Cytori Therapeutics Revenue in Adipose Derived Stem Cell Therapy Business (2015-2020)
    • 13.6.5 Cytori Therapeutics Recent Development and Reaction to COVID-19
  • 13.7 Intrexon
    • 13.7.1 Intrexon Company Details
    • 13.7.2 Intrexon Business Overview and Its Total Revenue
    • 13.7.3 Intrexon Adipose Derived Stem Cell Therapy Introduction
    • 13.7.4 Intrexon Revenue in Adipose Derived Stem Cell Therapy Business (2015-2020)
    • 13.7.5 Intrexon Recent Development and Reaction to COVID-19
  • 13.8 Mesoblast
    • 13.8.1 Mesoblast Company Details
    • 13.8.2 Mesoblast Business Overview and Its Total Revenue
    • 13.8.3 Mesoblast Adipose Derived Stem Cell Therapy Introduction
    • 13.8.4 Mesoblast Revenue in Adipose Derived Stem Cell Therapy Business (2015-2020)
    • 13.8.5 Mesoblast Recent Development and Reaction to COVID-19
  • 13.9 Pluristem Therapeutics
    • 13.9.1 Pluristem Therapeutics Company Details
    • 13.9.2 Pluristem Therapeutics Business Overview and Its Total Revenue
    • 13.9.3 Pluristem Therapeutics Adipose Derived Stem Cell Therapy Introduction
    • 13.9.4 Pluristem Therapeutics Revenue in Adipose Derived Stem Cell Therapy Business (2015-2020)
    • 13.9.5 Pluristem Therapeutics Recent Development and Reaction to COVID-19
  • 13.10 Tissue Genesis
    • 13.10.1 Tissue Genesis Company Details
    • 13.10.2 Tissue Genesis Business Overview and Its Total Revenue
    • 13.10.3 Tissue Genesis Adipose Derived Stem Cell Therapy Introduction
    • 13.10.4 Tissue Genesis Revenue in Adipose Derived Stem Cell Therapy Business (2015-2020)
    • 13.10.5 Tissue Genesis Recent Development and Reaction to COVID-19
  • 13.11 BioRestorative Therapies
    • 10.11.1 BioRestorative Therapies Company Details
    • 10.11.2 BioRestorative Therapies Business Overview and Its Total Revenue
    • 10.11.3 BioRestorative Therapies Adipose Derived Stem Cell Therapy Introduction
    • 10.11.4 BioRestorative Therapies Revenue in Adipose Derived Stem Cell Therapy Business (2015-2020)
    • 10.11.5 BioRestorative Therapies Recent Development and Reaction to COVID-19
  • 13.12 Celltex Therapeutics Corporation
    • 10.12.1 Celltex Therapeutics Corporation Company Details
    • 10.12.2 Celltex Therapeutics Corporation Business Overview and Its Total Revenue
    • 10.12.3 Celltex Therapeutics Corporation Adipose Derived Stem Cell Therapy Introduction
    • 10.12.4 Celltex Therapeutics Corporation Revenue in Adipose Derived Stem Cell Therapy Business (2015-2020)
    • 10.12.5 Celltex Therapeutics Corporation Recent Development and Reaction to COVID-19
  • 13.13 iXCells Biotechnologies
    • 10.13.1 iXCells Biotechnologies Company Details
    • 10.13.2 iXCells Biotechnologies Business Overview and Its Total Revenue
    • 10.13.3 iXCells Biotechnologies Adipose Derived Stem Cell Therapy Introduction
    • 10.13.4 iXCells Biotechnologies Revenue in Adipose Derived Stem Cell Therapy Business (2015-2020)
    • 10.13.5 iXCells Biotechnologies Recent Development and Reaction to COVID-19
  • 13.14 Pluristem Therapeutics
    • 10.14.1 Pluristem Therapeutics Company Details
    • 10.14.2 Pluristem Therapeutics Business Overview and Its Total Revenue
    • 10.14.3 Pluristem Therapeutics Adipose Derived Stem Cell Therapy Introduction
    • 10.14.4 Pluristem Therapeutics Revenue in Adipose Derived Stem Cell Therapy Business (2015-2020)
    • 10.14.5 Pluristem Therapeutics Recent Development and Reaction to COVID-19
  • 13.15 Cyagen
    • 10.15.1 Cyagen Company Details
    • 10.15.2 Cyagen Business Overview and Its Total Revenue
    • 10.15.3 Cyagen Adipose Derived Stem Cell Therapy Introduction
    • 10.15.4 Cyagen Revenue in Adipose Derived Stem Cell Therapy Business (2015-2020)
    • 10.15.5 Cyagen Recent Development and Reaction to COVID-19
  • 13.16 Lonza
    • 10.16.1 Lonza Company Details
    • 10.16.2 Lonza Business Overview and Its Total Revenue
    • 10.16.3 Lonza Adipose Derived Stem Cell Therapy Introduction
    • 10.16.4 Lonza Revenue in Adipose Derived Stem Cell Therapy Business (2015-2020)
    • 10.16.5 Lonza Recent Development and Reaction to COVID-19

14Analyst's Viewpoints/Conclusions

    15Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    Adipose tissue stem cells (ASCs), known as multipotent stem cells, are most commonly used in the clinical applications in recent years.
    Market Analysis and Insights: Global Adipose Derived Stem Cell Therapy Market
    Prior to COVID-19, the market for Adipose Derived Stem Cell Therapy was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of XX% during 2021–2026, whereas post-COVID-19 scenario, the market for Adipose Derived Stem Cell Therapy is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026. The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Adipose Derived Stem Cell Therapy market.

    Global Adipose Derived Stem Cell Therapy Scope and Market Size
    Adipose Derived Stem Cell Therapy market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Adipose Derived Stem Cell Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
    Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Adipose Derived Stem Cell Therapy market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
    This report also analyzes the impact of Coronavirus COVID-19 on the Adipose Derived Stem Cell Therapy industry.
    The following players are covered in this report:
    AlloCure
    Antria
    Celgene Corporation
    Cellleris
    Corestem
    Cytori Therapeutics
    Intrexon
    Mesoblast
    Pluristem Therapeutics
    Tissue Genesis
    BioRestorative Therapies
    Celltex Therapeutics Corporation
    iXCells Biotechnologies
    Pluristem Therapeutics
    Cyagen
    Lonza
    Adipose Derived Stem Cell Therapy Breakdown Data by Type
    Autologous Stem Cells
    Allogeneic Stem Cells
    Adipose Derived Stem Cell Therapy Breakdown Data by Application
    Therapeutic Application
    Research Application
    Buy now